Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2609782 | 0.91 | MAPK1 (0.56) | MAPK1KDM4ETSHRALDH1A1TDP1 | |
| SCHEMBL14901102 | 0.91 | MAPK1 (0.56) | MAPK1KDM4ETSHRALDH1A1TDP1 | |
| SCHEMBL14901101 | 0.91 | MAPK1 (0.56) | MAPK1KDM4ETSHRALDH1A1TDP1 | |
| SCHEMBL1982314 | 0.83 | MAPK1 (0.65) | MAPK1KDM4ETSHRALDH1A1TDP1 | |
| SCHEMBL13492168 | 0.83 | HSD17B10 (0.52) | MAPK1KDM4EHSD17B10USP2TDP1 | |
| SCHEMBL325805 | 0.81 | KDM4E (0.52) | KDM4EHSD17B10TSHRUSP2TDP1 | |
| SCHEMBL13492153 | 0.79 | CYP3A4 (0.46) | MAPK1HSD17B10TSHRUSP2ALDH1A1 | |
| Water SCHEMBL27734809 | 0.78 | KDM4E (0.50) | KDM4EHSD17B10TSHRUSP2TDP1 | |
| SCHEMBL16001419 | 0.78 | USP2 (0.52) | MAPK1KDM4EHSD17B10TSHRUSP2 | |
| SCHEMBL13492154 | 0.78 | USP2 (0.52) | MAPK1KDM4EHSD17B10TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | SCN1B, SCN3A, SCN5A | MAPK1 1375/4885KDM4E 1689/4885HSD17B10 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.